<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1892">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04646031</url>
  </required_header>
  <id_info>
    <org_study_id>T89-ROUSA-01</org_study_id>
    <nct_id>NCT04646031</nct_id>
  </id_info>
  <brief_title>Expanded Access to T89 for Treatment Use in Intermediate-size Patients Population With COVID-19</brief_title>
  <official_title>Expanded Access Use of T89 in An Intermediate-size Patients Population for the Treatment of Severe &quot;Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)&quot; Infection Disease Patients (COVID-19)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tasly Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tasly Pharmaceutical Group Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Tasly Pharmaceuticals, Inc.</source>
  <brief_summary>
    <textblock>
      This expanded access use program will provide a botanical drug of T89 for treatment use in an&#xD;
      intermediate-size population infected with SARS-CoV-2 who have severe COVID-19, or who are&#xD;
      judged by a healthcare provider to be at high risk of progression to severe or&#xD;
      life-threatening condition.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      T89 capsule is a botanical drug product for oral use. The drug substance of T89 capsule is&#xD;
      the water extract of two widely used herb medicines: Danshen (Radix Saliva Miltiorrhize Bge.,&#xD;
      RSM) and Sanqi (Radix Notoginseng, RN).&#xD;
&#xD;
      A large number of researches have shown that T89 has the effects of activating blood&#xD;
      circulation and removing blood stasis. Clinical trials conducted in China and US also show&#xD;
      that T89 can significantly improve blood oxygen saturation at high altitudes and alleviate&#xD;
      the symptoms of hypoxia. It has been also reported that T89 is effective in treating&#xD;
      myocardial ischemic diseases.&#xD;
&#xD;
      Basic studies show that T89 can improve red blood cell oxygen delivery capacity, reduce&#xD;
      reactive oxygen species (ROS) related tissue damage, alleviate tissue and organ injuries&#xD;
      caused by ischemia by improving microcirculation, improve energy metabolism and increase&#xD;
      adenosine triphosphate (ATP) production in myocardial tissue, inhibit the reduction of&#xD;
      hematocrit, albumin leakage, neutrophil CD18 and intercellular cell adhesion molecule-1&#xD;
      (ICAM-1), preventing deterioration of microcirculation caused by ischemia and hypoxia, and&#xD;
      inhibit platelet aggregation and adhesion.&#xD;
&#xD;
      The objective of this expanded access program is to provide T89 for treatment use in an&#xD;
      intermediate-size population with severe COVID-19, with the dosing regimen of 300mg (four T89&#xD;
      capsules) each time, orally, three time daily for 14 days, followed by a follow-up visit by&#xD;
      call on Day 21.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_intermediate>Yes</expanded_access_type_intermediate>
  </expanded_access_info>
  <condition>Covid19</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>T89 capsule</intervention_name>
    <description>T89 capsule, an medicinal product for oral use under active INDs in the US is a botanical drug containing 75mg active substance of the water extract of Danshen and Sanqi.</description>
    <other_name>Dantonic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Was hospitalized due to COVID-19 confirmed by positive testing of standard reverse&#xD;
             transcription-polymerase chain reaction (RT-PCR) assay;&#xD;
&#xD;
          -  Clinical signs indicative of severe systemic illness with COVID-19, such as&#xD;
             respiratory rate ≥30 per minute, heart rate ≥125 per minute, oxygen saturation by&#xD;
             pulse oximetry (SpO2) ≤86% on room air or PaO2/FiO2 &lt;300 (PaO2=Arterial oxygen&#xD;
             pressure, FiO2=Inspired oxygen fraction );&#xD;
&#xD;
          -  With at least one of following underlying diseases such as hypertension, diabetes, and&#xD;
             cardiovascular disease;&#xD;
&#xD;
          -  Oxygen therapy is clinically indicated at the start of screening.&#xD;
&#xD;
          -  Abnormal low platelet counts and/or other measurements indicative of systemic&#xD;
             thrombosis, such as platelet counts &lt;150,000/µL; 0.6 μg/mL&lt; D-dimer ≤2.0 μg/mL (i.e.,&#xD;
             1.2-4×upper limit of normal(ULN); ULN=0.5 μg/mL).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Requiring immediate intensive care unit (ICU) administration and treatment.&#xD;
&#xD;
          -  Need for high-flow nasal cannula oxygen delivery, noninvasive ventilation, invasive&#xD;
             mechanical ventilation or extracorporeal membrane oxygenation (ECMO).&#xD;
&#xD;
          -  Progression to death is imminent and inevitable within the next 24 hours, irrespective&#xD;
             of the provision of treatment.&#xD;
&#xD;
          -  Have known congenital hypercoagulopathy including but not limited to factor V Leiden&#xD;
             (FVL) homozygous and heterozygous, protein C or protein S deficiency. And patients who&#xD;
             have hypercysteinemia.&#xD;
&#xD;
          -  Have congenital bleeding disorder including but not limited to von Willebrand disease,&#xD;
             hemophilia A (factor VIII deficiency) hemophilia B (factor IX deficiency).&#xD;
&#xD;
          -  With alanine aminotransferase (ALT) ≥5×ULN, or aspartate aminotransferase (AST)&#xD;
             ≥5×ULN, or alkaline phosphatase (ALP) ≥5×ULN, or Total Bilirubin (TBILI) ≥2×ULN, or&#xD;
             platelet counts &lt;50,000/µL, or neutrophil counts &lt;1,000/µL.&#xD;
&#xD;
          -  Has severe preexisting pulmonary disease including but not limited to chronic&#xD;
             obstructive pulmonary disease (COPD), pulmonary fibrosis, pneumonectomy etc. Subjects&#xD;
             with extrinsic restrictive lung disease due to obesity can be enrolled.&#xD;
&#xD;
          -  With stage 4 severe kidney failure (i.e. estimated glomerular filtration rate (eGFR)&#xD;
             &lt;30) or requiring dialysis.&#xD;
&#xD;
          -  With congestive heart failure with New York Heart Association (NYHA).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Patrick Meehan, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MultiCare Health System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anni Li</last_name>
    <phone>301-978-3905</phone>
    <email>ALi@taslyUS.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Henry H Sun, PhD, MD</last_name>
    <phone>301-978-3899</phone>
    <email>HSun@taslyUS.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>MultiCare Health System</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Libby Bliss</last_name>
      <phone>253-403-8337</phone>
      <email>eabliss@multicare.org</email>
    </contact>
    <contact_backup>
      <last_name>Danielle Wahinekapu</last_name>
      <phone>253-403-3321</phone>
      <email>dwahinekapu@multicare.org</email>
    </contact_backup>
    <investigator>
      <last_name>Patrick Meehan, PhD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 24, 2020</study_first_submitted>
  <study_first_submitted_qc>November 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2020</study_first_posted>
  <last_update_submitted>November 24, 2020</last_update_submitted>
  <last_update_submitted_qc>November 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Twenty (20) patients with severe COVID-19 as participants</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

